NAD+ (NAD)

NAD+ (nicotinamide adenine dinucleotide) is a key coenzyme of cellular metabolism involved in 500+ enzymatic reactions. In preclinical models it activates sirtuins and supports mitochondrial function; clients self-report an energy boost and mental clarity. Clinical efficacy of the injectable form in humans has not been established — a free DOZA specialist consultation is available before starting.

There are no dedicated clinical statistics for injectable NAD+ — efficacy in humans has not been established (a 2026 systematic review found no outcome trials of IV or IM NAD+). DOZA clients most often report a subjective increase in energy, mental clarity and sleep quality during the course — these are individual self-reported impressions, not clinical trial results.

Pen Peptide produces NAD+ in three pen variants. Main manufacturer protocol (for 1200mg pen): 10 clicks × 2 times daily every other day, 30 days — 1 pen fully covers the course. For 500mg pen — 24 clicks × 2 times/day every other day. For 200mg pen — starter 10-day course with 20 clicks × 2 times/day, or 30-day with daily 7 clicks. Better to inject in morning or before 4 PM. Every other day is fundamental: NAD+ has cumulative effect. Break between courses 15–20 days. Optimal 2–3 courses per year. Exact scheme is selected by DOZA consultant.

NAD+ is the ready coenzyme, NMN is its oral precursor. NAD+ injection bypasses the GI tract, but the only human pharmacokinetic study (Grant et al., 2019) showed the molecule is rapidly cleaved in plasma into precursors that cells use for resynthesis. For NMN there are controlled human data: improved muscle insulin sensitivity in prediabetic women (Yoshino et al., Science 2021). No head-to-head "injection vs capsules" comparisons exist. DOZA client practice: NAD+ as a 30-day course 2–3 times/year, NMN for daily maintenance; choose the format with a consultant.

NAD+ and tirzepatide have different mechanisms: an energy-metabolism coenzyme vs a GLP-1/GIP receptor agonist. There are no controlled combination studies. Some DOZA clients on the Mounjaro program add NAD+ for energy support during caloric deficit — these are self-reported impressions. For your individual case — a free DOZA specialist consultation.

NAD+ is sensitive to LOW temperatures — DO NOT freeze. Pen Peptide manufacturer allows storage at room temperature (up to 25°C), avoiding direct sunlight. Optimal — in refrigerator at 2–8°C, but not in freezer. DOZA delivers pen in thermobox with cold chain, however short-term temperature deviations are not critical for NAD+ (stabilized MSSPT-formula).

Inject subcutaneously in abdomen or anterior thigh, rotating sites. Set pen programmer to required clicks (immediately 10 for 1200mg pen). Needle is short (4–6 mm), inserted at 90°. After injection — wait 10 seconds before withdrawing needle. Preferably inject in morning or before 4 PM — energy surge may interfere with falling asleep. On non-injection days just skip — NAD+ has cumulative effect through sirtuin activation. Before first injection — detailed DOZA specialist consultation with technique demonstration.

NAD+ does not affect the mechanism of semaglutide/tirzepatide and does not change appetite — these are different pathways. There are no controlled studies of combining NAD+ with GLP-1 drugs, so claims about "improved metabolic response" are not scientifically confirmed. The protocol hypothesis is to support energy during caloric deficit; some clients report a subjective energy boost (self-reported). If considering the combination, a sensible option is to start NAD+ 2–3 weeks after starting GLP-1, once the body has adapted; start with a DOZA specialist consultation.

An NAD+ IV drip is an in-clinic procedure: a session takes 2–6 hours, in Kyiv usually from ₴3,000 per session, with several visits needed. The Pen Peptide pen means subcutaneous micro-injections at home per the manufacturer protocol, from ₴5,600 per pen. No direct clinical comparisons of the formats exist; IV NAD+ pharmacokinetics (Grant et al., 2019) shows rapid cleavage of the molecule in plasma regardless of administration route. DOZA offers the pen format for convenience, precise click dosing and lower course cost.

These are two forms of the same coenzyme: NAD+ is the oxidized form (accepts electrons), NADH is the reduced form (donates electrons in the mitochondrial respiratory chain). In the cell they constantly interconvert. The DOZA product is NAD+ in a Pen Peptide pen. Standalone "NADH" tablet supplements are a different format with its own pharmacokinetics; no comparative studies with injectable NAD+ exist.

NAD+ is not FDA-approved as a drug. Current status (verified August 2026): NAD is listed in Category 1 of substances nominated for pharmacy compounding under FDA section 503A (list update of April 22, 2026) — "under evaluation" with interim enforcement discretion; this is neither an approval nor a final determination. Beta-NAD disodium salt is listed separately in Category 3 (nominated without adequate support), and NAD+ is not permitted for 503B outsourcing facilities. It is not registered as a medicine in Ukraine — it is sold as a research-grade product. That is why DOZA accompanies every course with a free specialist consultation.